Description
Deucravacitinib
Each film-coated tablet contains: Deucravacitinib. … 6mg.
INDICATION
LuciDeucra is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DOSAGE AND USE
• For recommended evaluation prior to LuciDeucra initation, see Full Prescribing Information. • Recommended dosage is 6 mg orally once daily, with or without food. Limitations of Use: Not recommended for use in combination with other potent immunosuppressants.
STORAGE
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING
Keep medicine out of reach of Children. Do not administer LuciDeucra during Pregnancy and Lactation.
Reviews
There are no reviews yet.